View Archive »
About The Cover
The cover of the October issue of Oncotarget features the first figure from Couty et al. showing chimera and native PKA-S6K1.
|
|
Table of Contents
Editorial Materials
|
| In vivo selection of tumorspecific antibodies |
|
https://doi.org/10.18632/oncotarget.1407
|
| 1547 |
|
| Estrogen response in luminal breast cancer |
|
https://doi.org/10.18632/oncotarget.1354
|
| 1548-1549 |
|
| Cytokineinduced ‘bystander’ senescence in DDR and immunosurveillance |
|
https://doi.org/10.18632/oncotarget.1487
|
| 1552-1553 |
|
| Ribosomes: the future of targeted therapies |
|
https://doi.org/10.18632/oncotarget.1511
|
| 1554-1555 |
Reviews
|
| Lysinespecific modifications of p53: a matter of life and death |
|
https://doi.org/10.18632/oncotarget.1436
|
| 1556-1571 |
Research Papers
|
| The predictive value of 53BP1 and BRCA1 mRNA expression in advanced nonsmallcell lung cancer patients treated with firstline platinumbased chemotherapy |
|
https://doi.org/10.18632/oncotarget.1157
|
| 1572-1581 |
|
| High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients |
|
https://doi.org/10.18632/oncotarget.1050
|
| 1582-1591 |
|
| Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer |
|
https://doi.org/10.18632/oncotarget.1148
|
| 1592-1605 |
|
| Smallmolecule targeting of translation initiation for cancer therapy |
|
https://doi.org/10.18632/oncotarget.1186
|
| 1606-1617 |
|
| Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 downregulation in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.1221
|
| 1618-1631 |
|
| The FAK scaffold inhibitor C4 disrupts FAKVEGFR3 signaling and inhibits pancreatic cancer growth |
|
https://doi.org/10.18632/oncotarget.1365
|
| 1632-1646 |
|
| The discovery of potent ribosomal S6 kinase inhibitors by highthroughput screening and structureguided drug design |
|
https://doi.org/10.18632/oncotarget.1255
|
| 1647-1661 |
|
| HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma |
|
https://doi.org/10.18632/oncotarget.1232
|
| 1662-1672 |
|
| Regulation of histone H2AZ expression is mediated by sirtuin 1 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.1237
|
| 1673-1685 |
|
| Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration |
|
https://doi.org/10.18632/oncotarget.1265
|
| 1686-1697 |
|
| Lung cancer tumorigenicity and drug resistance are maintained through ALDHhi CD44hi tumor initiating cells |
|
https://doi.org/10.18632/oncotarget.1246
|
| 1698-1711 |
|
| DHHRHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3GLIS2positive acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.1280
|
| 1712-1720 |
|
| Substantial expression of luteinizing hormonereleasing hormone LHRH receptor type I in human uveal melanoma |
|
https://doi.org/10.18632/oncotarget.1379
|
| 1721-1728 |
|
| Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine |
|
https://doi.org/10.18632/oncotarget.1412
|
| 1729-1736 |
|
| 5azacytidine reduces methylation promotes differentiation and induces tumor regression in a patientderived IDH1 mutant glioma xenograft |
|
https://doi.org/10.18632/oncotarget.1408
|
| 1737-1747 |
|
| CCAT2 a novel long noncoding RNA in breast cancer: expression study and clinical correlations |
|
https://doi.org/10.18632/oncotarget.1292
|
| 1748-1762 |
|
| Identification of novel small molecule inhibitors of centrosome clustering in cancer cells |
|
https://doi.org/10.18632/oncotarget.1198
|
| 1763-1776 |
|
| Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyuryyeast vaccine |
|
https://doi.org/10.18632/oncotarget.1295
|
| 1777-1790 |
|
| Upregulation of adenylate cyclase 3 ADCY3 increases the tumorigenic potential of cells by activating the CREB pathway |
|
https://doi.org/10.18632/oncotarget.1324
|
| 1791-1803 |
|
| Cholesterolinduced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation |
|
https://doi.org/10.18632/oncotarget.1364
|
| 1804-1818 |
|
| Identification of a novel peptide that blocks basic fibroblast growth factormediated cell proliferation |
|
https://doi.org/10.18632/oncotarget.1312
|
| 1819-1828 |
|
| Broadspectrum antitumor and antimetastatic DNA vaccine based on p62encoding vector |
|
https://doi.org/10.18632/oncotarget.1397
|
| 1829-1835 |
|
| The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer NSCLC recurrence and metastasis |
|
https://doi.org/10.18632/oncotarget.1282
|
| 1836-1843 |
|
| PTRF/Cavin1 decreases prostate cancer angiogenesis and lymphangiogenesis |
|
https://doi.org/10.18632/oncotarget.1300
|
| 1844-1855 |
Letters to the Editor
|
| Insights into therapeutic resistance from wholegenome analyses of circulating tumor DNA |
|
https://doi.org/10.18632/oncotarget.1486
|
| 1856-1857 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
